PRNewsWire
12 Mar 2026, 14:00 UTC · 33w ago
Verdict
Headline leans bearish. We score MREO −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Mereo BioPharma's Orbit and Cosmic Phase 3 studies failed to achieve statistical significance or meet their primary endpoints regarding fracture rate reduction.
More negative than 99% of claims this week
A class action lawsuit has been filed against Mereo BioPharma alleging securities fraud or unlawful business practices.
Continue reading
5 related stories
More negative than 99% of ticker scores this week
Scored by the NIS engine · methodology.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is facing a class action lawsuit following failed Phase 3 clinical trials and a massive collapse in share price.
More negative than 81% of ticker scores this week
The company is under investigation by a law firm on behalf of investors.
More negative than 81% of ticker scores this week
The company is under investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9m ago
−27.1%
Price agrees with the score
$0.2910 vs $0.3990 close before publication (Mar 11) · not market-adjusted
MREO chart →
